Corient Private Wealth
CHRS icon

Corient Private Wealth’s Coherus Oncology CHRS Stock Holding History

Corient Private Wealth’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Sell
100,002
-79,998
-44% -$142K ﹤0.01% 2600
2025
Q4 		$256K Buy
180,000
+90,000
+100% +$131K ﹤0.01% 2539
2025
Q3 		$148K Buy
90,000
+30,000
+50% +$33.4K ﹤0.01% 2398
2025
Q2 		$43.9K Buy
60,000
+10,000
+20% +$8.63K ﹤0.01% 2393
2025
Q1 		$40.4K Hold
50,000
– – ﹤0.01% 2236
2024
Q4 		$69K Hold
50,000
– – ﹤0.01% 2256
2024
Q3 		$52K Buy
50,000
+20,000
+67% +$27.4K ﹤0.01% 2393
2024
Q2 		$51.9K Buy
+30,000
New +$60.4K ﹤0.01% 2256

Other funds holding CHRS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return